Categories: News

Inogen to Announce Second Quarter 2021 Financial Results on August 4, 2021

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release second quarter 2021 financial results after market close on Wednesday, August 4, 2021. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.

Individuals interested in listening to the conference call may do so by dialing (877) 841-3961 for domestic callers or (201) 689-8589 for international callers. Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen’s website at: http://investor.inogen.com/.

A replay of the call will be available beginning August 4, 2021 at 3:30pm PT/6:30pm ET through 3:30pm PT/6:30pm ET on August 18, 2021. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13721387. The webcast will also be available on Inogen’s website for one year following the completion of the call.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

We are a medical technology company offering innovative respiratory products for use in the homecare setting. We primarily develop, manufacture and market innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Contacts

Investor Relations & Media Contact:
Ali Bauerlein

ir@inogen.net

Staff

Recent Posts

Project 55 Launches Free Mental Health First Responder Training for Public Use

Evidence-informed course equips non-professionals to respond to mental health crises with practical, scalable skills Project…

1 hour ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or…

1 hour ago

Precision Neuroscience Expands Leadership Team With Key Hires From Meta and FDA

Vanessa Tolosa joins as Senior Vice President of Research and Development; Vivek Pinto as Director…

1 hour ago

Management Confidence: Shineco Executives Launch up to $2M Open-Market Stock Purchase Program

BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI),…

1 hour ago